| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Tempus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $3.06B | Series G-5 | 4/30/2024 | $200MM | $8.89B | $57.31 | Softbank | ||||
 | Hinge Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $2.54B | Series E | 10/28/2021 | $400MM | $6.2B | $77.46 | Coatue Management, Tiger Global Management | ||||
 | Lyell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.04B | Series C | 3/5/2020 | $493MM | $2.5B | $11.49 | ARCH Venture Partners, Foresite Capital, Milky Way Investments | ||||
 | Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $812.92MM | Series C | 1/21/2025 | $399.4MM | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | ||||
 | Eikon Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.16B | Series D | 2/14/2025 | $350.7MM | $1.85B | $5.84 | Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, T. Rowe Price, UC Investments | ||||
 | One Medical Group | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $437.68MM | Series I | 8/22/2018 | $250MM | $1.5B | $12.43 | The Carlyle Group | ||||
 | Adaptive Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $561.37MM | Series F-1 | 1/4/2018 | $45MM | $1.35B | $10.67 | Microsoft | ||||
 | 10x Genomics, Inc. | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $222.59MM | Series D-1 | 1/7/2019 | $35MM | $1.34B | $12.73 | Meritech Capital, Fidelity, Wells Fargo | ||||
 | Neumora | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $612.4MM | Series B | 10/11/2022 | $112.4MM | $1.33B | $1.50 | Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners | ||||
 | BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $396.39MM | Series D | 6/21/2024 | $130.47MM | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | ||||
 | Prime Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $315.76MM | Series B | 7/13/2021 | $200MM | $1.23B | $4.38 | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price | ||||
 | American Well | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $674MM | Series C | 5/20/2020 | $617MM | $1.03B | $45.00 | InVenture Partners, Anthem, Teva Pharmaceutical Industries, Allianz X, Philips, Martin Ventures, Hanaco Venture Capital, Cito Ventures, ADIP, Echo Health Ventures, McKesson Ventures, Waterline Ventures, Westway Capital, SV Health Investors | ||||
 | Omada Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $444.57MM | Series E | 2/23/2022 | $197.55MM | $1.01B | $17.99 | Fidelity, aMoon, Perceptive Advisors, Wellington Management, Civilization Ventures | ||||
 | MapLight Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $511MM | Series D | 9/30/2025 | $200MM | $883.21MM | $0.95 | Catalyst4, Forbion, Sanofi, Novo Holdings | ||||
 | Fractyl | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $572.96MM | Series F | 6/16/2021 | $100MM | $872.9MM | $8.38 | Maverick Capital, M28 Capital, Population Health Partners | ||||
 | PROCEPT BioRobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $341.8MM | Series G | 6/30/2021 | $85MM | $872.62MM | $4.02 | Fidelity, T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors LP, Duquesne Family Office | ||||
 | Livongo | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $237.65MM | Series E | 4/23/2018 | $105MM | $796.49MM | $8.30 | General Catalyst, KinnevikMerck, Global Health Innovation Fund, Wanxiang America, M12, Echo Health Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Kleiner Perkins and Draper Fisher Jurvetson Management | ||||
 | Alumis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.66B | Series C | 3/6/2024 | $259MM | $702.67MM | $3.14 | Foresite Capital, Samsara BioCapital, venBio Partners, Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, Piper Heartland Healthcare, AyurMaya Capital Management | ||||
 | Upstream Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $800MM | Series B | 6/8/2023 | $200MM | $676.16MM | $17.00 | Enavate Sciences, Venrock Healthcare Capital Partners, Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $510.76MM | Series F | 8/2/2023 | $105.02MM | $615.24MM | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Maze Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $503.77MM | Series D | 12/3/2024 | $76.4MM | $552.39MM | $1.38 | Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital | ||||
 | HeartFlow | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $755.52MM | Series F | 4/6/2023 | $174.86MM | $546.5MM | $2.85 | Bain Capital, Janus Henderson Investors, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management | ||||
 | Amylyx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $203.25MM | Series C-1 | 7/20/2021 | $107.33MM | $541.01MM | $10.27 | Viking Global Investors, Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund, Falcon Edge, Morningside Ventures, 683 Capital Management, Belinda Termeer, Polaris Founders Capital | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $331.32MM | Series C | 3/6/2024 | $181.86MM | $523.7MM | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||